ADAM17 and hepatocellular carcinoma: These results provide evidence that ADAM17 inhibits the migration and metastatic potential of CD133-expressing liver CSCs after radiotherapy and may serve as a prognostic marker of recurrence and metastasis of HCC following radiotherapy.